Biotech | 08 April 2026
Stipple Bio raises $100M Series A to advance next-gen cancer therapies
The new capital is expected to fund the company through 2029
The new capital is expected to fund the company through 2029
EB-003 is Enveric’s lead neuroplastogen, a 5-HT2A / 5-HT1B dual-acting compound designed to promote neuroplastic changes
Move aligns global biologics identity under the Biocon Biologics brand
Safety was equally impressive. ENV-294 was well tolerated
Minister highlights scope for domestic manufacturing during his meeting with Dr Niti Pall, President-elect, International Diabetes Federation
Rs 66 lakh acquisition will support DNA engineering and novel cell-gene therapy alternatives to conventional chemotherapy
The company has highlighted setbacks in Phase II studies while outlining fresh regulatory and late-stage development plans for Fibromun and Nidlegy
DBT-BIRAC, BioE3 and the Rs 10,000-crore Biopharma SHAKTI scheme aim to accelerate innovation, biomanufacturing and exports
A joint position paper warns that Europe is the only major global region without a dedicated biomanufacturing initiative
Empowering 15 Women in STEM (Life Sciences) with scholarship, internship and mentorship
As of December 31, 2025, the company reported total cash, cash equivalents and short-term investments of approximately $4.94 million
Lonza will take on technology transfer, process optimization, and cGMP manufacturing, leveraging its global network and expertise in highly potent compounds
The investigational new drug application with FDA was actually for NEOK002, an EGFR/MUC1-targeting antibody-drug conjugate aimed at solid tumors
Capital infusion to accelerate Earendil’s R&D platform
The move comes as the global biotech and biopharma CDMO market continues to surge, fueled by rising demand
The protections extend through at least 2035, with the potential for further extensions
Subscribe To Our Newsletter & Stay Updated
